4.1 Upper GI Symptoms: Anorexia, Early Satiety, Nausea, & Vomiting
Key Takeaways
- CINV is classified into acute (<24 hours post-chemo, serotonin/5-HT3 mediated), delayed (24-120 hours, Substance P/NK1 mediated), anticipatory (conditioned cortical sensory response), breakthrough, and refractory.
- High emetogenic risk chemotherapy (>90% CINV incidence, e.g., cisplatin, AC regimen) requires a mandatory 4-drug prophylactic antiemetic regimen combining a 5-HT3 receptor antagonist, NK1 receptor antagonist, dexamethasone, and olanzapine.
- Medical Nutrition Therapy (MNT) for CINV emphasizes 5-6 small frequent meals, cold or room-temperature foods to minimize volatile odor compounds, dry bland starches, strict dietary fat restriction, and separating fluid intake from solid meals by 30-60 minutes.
- Early satiety and gastroparesis in oncology stem from autonomic neuropathy, vinca alkaloids, or tumor-induced gastric compression; management requires nutrient-dense liquid calories between meals, prokinetic agents (metoclopramide), and light preprandial physical activity.
4.1 Upper GI Symptoms: Anorexia, Early Satiety, Nausea, & Vomiting
Upper gastrointestinal toxicities—specifically Chemotherapy-Induced Nausea and Vomiting (CINV), early satiety, delayed gastric emptying, and cancer-related anorexia—are among the most distressing side effects reported by oncology patients. Uncontrolled upper GI symptoms rapidly lead to compromised oral intake, acute dehydration, electrolyte derangements, weight loss, and premature treatment interruptions. Mastering the physiological pathways, emetogenic risk categories, antiemetic pharmacotherapy, and targeted Medical Nutrition Therapy (MNT) is critical for Board Certified Specialists in Oncology Nutrition (CSO).
Neurophysiology & Classification of CINV
CINV is triggered through two main pathways: the peripheral pathway (activated primarily by enterochromaffin cells in the gastrointestinal mucosa) and the central pathway (activated in the Chemoreceptor Trigger Zone [CTZ] in the area postrema of the fourth ventricle and the vomiting center in the medulla oblongata). Selecting appropriate antiemetics and timing nutrition interventions requires understanding the temporal classification and underlying neurotransmitters.
| CINV Category | Onset & Timing | Dominant Neurotransmitter & Primary Pathway | Clinical Features & First-Line Management |
|---|---|---|---|
| Acute CINV | Within minutes to <24 hours post-chemotherapy (peaking at 5–6 hours) | Serotonin (5-HT) released from damaged mucosal enterochromaffin cells binding 5-HT3 receptors on vagal afferents | Peripherally driven; highly predictable. Prevented with 5-HT3 receptor antagonists (e.g., ondansetron, palonosetron) plus dexamethasone. |
| Delayed CINV | 24 to 120 hours (1–5 days) post-chemotherapy (peaking at 48–72 hours) | Substance P binding central Neurokinin-1 (NK1) receptors in the CTZ and solitary tract nucleus | Centrally driven; common with cisplatin, carboplatin, cyclophosphamide, and doxorubicin. Requires NK1 receptor antagonists (aprepitant) and olanzapine. |
| Anticipatory CINV | Prior to chemotherapy administration (hours to days before cycle) | Conditioned sensory response involving limbic system and cerebral cortex memory networks | Triggered by sights, smells, or sounds of the infusion clinic from poor CINV control in prior cycles. Treated with behavioral therapy/desensitization and lorazepam (benzodiazepine). |
| Breakthrough CINV | Occurs despite optimal baseline prophylactic antiemetics | Multiple overlapping pathways (dopaminergic, histaminergic, serotonergic, muscarinic) | Requires adding a rescue antiemetic from a different drug class (e.g., oral olanzapine 5–10 mg, prochlorperazine, or metoclopramide). |
| Refractory CINV | Occurs during subsequent cycles after prophylactic and rescue regimens fail | Persistent multi-receptor activation | Requires upgrading the baseline prophylactic regimen for all future chemotherapy cycles (e.g., advancing from 3-drug to 4-drug protocol). |
Emetogenic Risk Stratification of Antineoplastic Regimens
According to Multinational Association of Supportive Care in Cancer (MASCC), European Society for Medical Oncology (ESMO), and American Society of Clinical Oncology (ASCO) consensus guidelines, intravenous antineoplastic agents are categorized into four distinct emetogenic risk levels based on the proportion of patients experiencing acute emesis in the absence of antiemetic prophylaxis:
-
High Emetogenic Risk (>90% incidence of emesis):
- Cisplatin (single dose $\ge 50\text{ mg/m}^2$)
- Anthracycline + Cyclophosphamide (AC) Combination (e.g., doxorubicin or epirubicin + cyclophosphamide in breast cancer)
- Dacarbazine, Streptozocin, High-dose Cyclophosphamide ($>1500\text{ mg/m}^2$), Ifosfamide ($>2\text{ g/m}^2/\text{dose}$)
- Mandatory Prophylaxis: 4-Drug Regimen consisting of a 5-HT3 RA + NK1 RA + Dexamethasone + Olanzapine (10 mg daily on days 1–4).
-
Moderate Emetogenic Risk (30% to 90% incidence of emesis):
- Carboplatin (AUC $\ge 4$), Oxaliplatin, Irinotecan, Epirubicin
- Cyclophosphamide ($<1500\text{ mg/m}^2$), Cytarabine ($>1\text{ g/m}^2$), Methotrexate ($>250\text{ mg/m}^2$)
- Prophylaxis: 2- or 3-Drug Regimen combining a 5-HT3 RA + Dexamethasone $\pm$ NK1 RA (NK1 RA is mandatory for carboplatin AUC $\ge 4$).
-
Low Emetogenic Risk (10% to 30% incidence of emesis):
- Paclitaxel, Docetaxel, 5-Fluorouracil (5-FU), Gemcitabine, Etoposide, Topotecan, Pemetrexed
- Prophylaxis: Single-agent antiemetic (e.g., dexamethasone 8 mg OR a 5-HT3 RA prior to chemotherapy).
-
Minimal Emetogenic Risk (<10% incidence of emesis):
- Monoclonal Antibodies (Rituximab, Bevacizumab, Trastuzumab, Cetuximab), Vincristine, Vinblastine, Bleomycin
- Prophylaxis: No routine baseline antiemetic prophylaxis recommended; rescue antiemetics available PRN.
Antiemetic Pharmacotherapy Profiles
- 5-HT3 Receptor Antagonists (Ondansetron, Granisetron, Palonosetron): Selectively block 5-HT3 receptors peripherally on vagal nerve terminals and centrally in the CTZ. Palonosetron is a second-generation antagonist with a long half-life (~40 hours) and allosteric binding affinity, making it superior for controlling delayed emesis in moderate emetogenic regimens.
- NK1 Receptor Antagonists (Aprepitant, Fosaprepitant, Netupitant): Block Substance P binding to central NK1 receptors. Essential for preventing delayed CINV in high-risk regimens. Aprepitant is a moderate CYP3A4 inhibitor, requiring a 50% dose reduction of co-administered IV dexamethasone.
- Corticosteroids (Dexamethasone): Exerts antiemetic effects through prostaglandin inhibition, reduction of blood-brain barrier permeability, and central inflammatory blockade. Dramatically enhances 5-HT3 and NK1 antagonist efficacy.
- Olanzapine (Atypical Antipsychotic): Blocks multiple receptors including dopamine ($D_2$), serotonin ($5\text{-HT}_{2c}, 5\text{-HT}_3$), histamine ($H_1$), and muscarinic receptors. Administered at 5–10 mg orally daily on Days 1–4 of high emetogenic chemotherapy and as rescue therapy for breakthrough nausea.
Pathophysiology & Management of Early Satiety & Gastroparesis
Early satiety (feeling full after consuming only a few bites of food) and delayed gastric emptying (gastroparesis) in oncology stem from multiple mechanical and neurological factors:
- Autonomic Neuropathy & Vinca Alkaloid Toxicity: Chemotherapy agents such as vincristine and paclitaxel cause autonomic nerve damage, reducing gastric motility and antral contractions.
- Opioid-Induced Gastric Hypomotility: Narcotic analgesics impair gastrointestinal tone and slow gastric emptying.
- Tumor Extrinsic Compression: Large abdominal tumors (gastric, pancreatic, ovarian, retroperitoneal sarcoma) physically compress the stomach, reducing functional gastric volume.
- Pharmacological Prokinetics: Metoclopramide (5–10 mg TID before meals) acts as a dopamine $D_2$ antagonist and $5\text{-HT}_4$ agonist, stimulating gastric emptying and antral contractions. Short-term Erythromycin (125–250 mg TID) acts as a motilin receptor agonist to accelerate gastric transit.
Medical Nutrition Therapy (MNT) Protocols for Upper GI Symptoms
MNT Protocol for Nausea and Vomiting
- Meal Frequency & Volume: Consume 5 to 6 small, frequent meals throughout the day. An empty stomach permits gastric acid accumulation and gastric dysrhythmias, exacerbating nausea.
- Temperature Modulation: Serve foods cold or at room temperature (e.g., chilled chicken salad, hard-boiled eggs, yogurt, smoothies, pudding). Cold foods produce significantly fewer volatile odor compounds that trigger cortical nausea centers.
- Odor & Texture Control: Avoid food preparation odors. Emphasize bland, dry starches (plain toast, crackers, pretzels, dry cereal, white rice) which absorb gastric secretions.
- Dietary Fat Regulation: Strictly limit high-fat, fried, greasy, or heavy foods. High-fat meals stimulate cholecystokinin (CCK) release, delaying gastric emptying and increasing gastric distension.
- Fluid Management Protocol: Separate fluid intake from solid meals by 30 to 60 minutes. Drinking large liquid volumes with meals causes immediate gastric distension, accelerating nausea and emesis. Encourage small sips of cool, clear, or carbonated fluids (ginger ale, peppermint tea, electrolyte solutions) between meals.
- Botanical Supplementation: Ginger (Zingiber officinale) at doses of 1.0 to 1.5 grams daily in divided doses (capsules or teas) reduces acute chemotherapy nausea by modulating serotonergic and cholinergic receptors.
MNT Protocol for Early Satiety & Anorexia
- Nutrient-Dense Fortification: Maximize caloric density in small food volumes by adding healthy fats (olive oil, nut butter, avocado), skim milk powder, or modular protein powders to soups, oatmeal, and purees.
- Liquid Calorie Strategy: Utilize high-calorie, high-protein commercial oral nutritional supplements (ONS) or homemade fortified smoothies ingested slowly between meals to meet daily targets without prematurely distending the stomach.
- Preprandial Physical Activity: Encourage light physical activity (e.g., a 10 to 15 minute walk) prior to meals to enhance gastric accommodation and stimulate physiological hunger cues.
Clinical Case Scenario & Worked Care Plan
Patient Profile: A 58-year-old female with Stage III non-small cell lung cancer receiving Cisplatin ($75\text{ mg/m}^2$) and Pemetrexed. She reports severe nausea, two episodes of emesis 48 hours post-chemotherapy, and early satiety after 3 bites of food. Weight loss is 6% over 4 weeks.
Care Plan Analysis:
- Emetogenic Assessment: Cisplatin $\ge 50\text{ mg/m}^2$ is High Emetogenic Risk (>90%). Her delayed emesis at 48 hours indicates inadequate delayed CINV prophylaxis.
- Pharmacotherapy Recommendation: Upgrade baseline antiemetic coverage to the mandatory 4-drug regimen: 5-HT3 RA (Palonosetron 0.25 mg IV Day 1) + NK1 RA (Aprepitant 125 mg Day 1, 80 mg Days 2–3) + Dexamethasone (8 mg Days 1–4) + Olanzapine (5 mg PO daily Days 1–4).
- MNT Interventions: Implement 6 small meals/day, separate liquids from solids by 45 minutes, prescribe high-protein liquid ONS between meals (providing 300 kcal, 15g protein per 8 oz), and initiate pre-meal 10-minute walks.
A patient receiving single-agent Cisplatin at a dose of 75 mg/m² experiences severe nausea and vomiting 48 hours after chemotherapy infusion. Which neurotransmitter pathway and antiemetic drug class are primarily responsible for preventing this delayed CINV response?
Which antineoplastic regimen is classified as having a HIGH emetogenic risk (>90% frequency of acute emesis without antiemetic prophylaxis)?
What is the primary rationale for instructing a patient with chemotherapy-induced nausea to separate liquid intake from solid food meals by 30 to 60 minutes?
A patient with autonomic neuropathy secondary to vincristine therapy presents with severe early satiety, postprandial fullness, and bloating after small meals. Which pharmacological prokinetic agent and MNT strategy are most appropriate?